Abstract
We report the efficacy and adverse effect profile of intraduodenal levodopa-carbidopa intestinal gel (LCIG) infusion from patients treated in a single Australian movement disorder centre. We conducted an open-label, 12 month prospective study of treatment with LCIG in patients with advanced Parkinson's disease in a single tertiary referral hospital unit specialising in movement disorders. Patients with levodopa-responsive, advanced Parkinson's disease with motor fluctuations despite optimal pharmacological treatment were enrolled and underwent a 16 hour daily infusion of LCIG for 12 months. Fifteen participants completed the trial. The mean (± standard deviation) improvement in Unified Parkinson's Disease Rating Scale part III was 37 ± 11%, mean daily "off" period reduced from 6.3 ± 2 to 1.9 ± 2 hours, total daily "on" time increased from 10.2 ± 3 to 13.7 ± 2 hours, "on" period without dyskinesia increased from 4.5 ± 3 to 7.5 ± 5 hours, and 39-item Parkinson's Disease Questionnaire Summary Index score improved by 32.5 ± 35%. The most common adverse event was reversible peripheral neuropathy secondary to vitamin B12 ± B6 deficiency (40%), local tube problems (40%), and impulse control disorder (ICD) (27%). No patient had stoma b...Continue Reading
References
Mar 1, 1988·Neurology·R KurlanI Shoulson
Nov 6, 2004·Science·Michael J FrankRandall C O'reilly
Jan 26, 2005·Neurology·D NyholmH Askmark
Jul 15, 2009·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Paul SilbersteinUNKNOWN Australian DBS Referral Guidelines Working Group
Sep 19, 2009·Parkinsonism & Related Disorders·V PuenteR Campo
May 28, 2011·Acta Neurologica Scandinavica·D Santos-GarcíaR de la Fuente-Fernández
Jul 26, 2011·Journal of Neural Transmission·Fabian KlostermannFrank Marzinzik
Jan 5, 2013·Parkinsonism & Related Disorders·Hubert H FernandezRobert A Lenz
Jan 5, 2013·Journal of Neurology·Jens VolkmannWolfgang Oertel
Citations
May 4, 2016·CNS Drugs·Karin WirdefeldtDag Nyholm
Feb 12, 2017·Parkinsonism & Related Disorders·Annamária JuhászNorbert Kovács
Mar 21, 2018·Journal of Neurology·Maria Jose CatalanUNKNOWN EDIS Study Group
Sep 5, 2018·Acta Neurologica Scandinavica·Ilias ThomasDag Nyholm
Jul 2, 2018·BMJ Case Reports·Paolo CerroneCarmine Marini
Feb 15, 2019·Neurologia Medico-chirurgica·Tetsuya AsakawaHiroki Namba
Jun 1, 2019·Expert Review of Neurotherapeutics·Carmine VitaleGabriella Santangelo
Sep 2, 2017·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Marie Grall-BronnecGaëlle Challet-Bouju
May 10, 2020·Acta Neurologica Scandinavica·Claas EhlersHolger Honig
Jul 18, 2020·Brain and Behavior·Walaa A Kamel, Jasem Y Al-Hashel
Jun 9, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Walter MaetzlerMalcolm Horne
Apr 14, 2020·Journal of Parkinson's Disease·Simone SimoniNicola Tambasco
Mar 28, 2017·Therapeutic Advances in Neurological Disorders·Johan Virhammar, Dag Nyholm
Mar 7, 2019·Movement Disorders Clinical Practice·Alberto RomagnoloLeonardo Lopiano
Nov 28, 2018·NPJ Parkinson's Disease·Belinda CruseVictor S C Fung
Nov 2, 2019·Revue neurologique·A-S BlaiseL Defebvre
Jan 7, 2020·Biomaterials·Govindarajan KarthivashanDong-Kug Choi
Apr 27, 2021·Movement Disorders : Official Journal of the Movement Disorder Society·Taiji TsunemiNobutaka Hattori
May 22, 2021·Advances in Therapy·Angelo AntoniniK Ray Chaudhuri